Viyash Scientific Ltd
NSE: VIYASH · Pharma - CDMO/API
Snapshot
Unlock Viyash Scientific Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sequent Scientific Limited is a global animal health company specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished formulations. Its product portfolio covers a wide range of therapeutic areas including anthelmintics, anti-infectives, and nutraceuticals, alongside analytical testing services for the pharmaceutical and personal care sectors.
Business Model
The company generates revenue through the sale of animal health APIs and finished dosage forms, supported by a global manufacturing and distribution footprint. Additionally, it provides specialised analytical solutions, including method validation and stability testing, to external pharmaceutical and nutraceutical organisations.
Growth Outlook
Growth is driven by the expansion of its animal health product portfolio and the increasing demand for high-quality veterinary APIs and formulations globally. The company continues to leverage its analytical capabilities to support both internal development and external client requirements.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent global regulatory standards for pharmaceutical manufacturing and the potential for audits impacting production.
- Input Cost Volatility. Fluctuations in the prices of raw materials and key starting materials for APIs can significantly impact profit margins.
- Foreign Exchange Risk. As a global player with significant international operations, the company is exposed to currency fluctuations that may affect financial performance.
- Competitive Landscape. The animal health sector is highly competitive, requiring continuous investment in research and development to maintain market share.
Start your research today
Unlock AI insights, financials, peers and live data on Viyash Scientific Ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,644 Cr
TTM · consolidated
NET PROFIT
₹152 Cr
TTM · consolidated
EPS
₹3.25
TTM · consolidated
RETURN ON EQUITY
8.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
13.0%
TTM · consolidated
P/E
81.8x
Q4 FY26 · consolidated
EV/EBITDA
23.4x
Q4 FY26 · consolidated
EBITDA MARGIN
19.1%
TTM · consolidated
NET PROFIT MARGIN
7.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.1x
Q4 FY26 · consolidated
Peers · Pharma - CDMO/API
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Viyash Scientific LtdVIYASH | ₹11,614 Cr | 81.80 | 23.42 | 70.4% | 19.1% | 8.4% | 13.0% | +50.1% |
Alivus Life Sciences LtdALIVUS | ₹16,770 Cr | 27.82 | 18.42 | 7.9% | 35.1% | 19.6% | 25.1% | +47.1% |
Jubilant Ingrevia Ltd.JUBLINGREA | ₹10,836 Cr | 34.82 | 17.24 | 11.0% | 14.3% | 10.2% | 12.4% | -7.0% |
As of Q4 FY26
Financials
Viyash Scientific Ltd
NSE: VIYASH · Pharma - CDMO/API
Snapshot
Unlock Viyash Scientific Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sequent Scientific Limited is a global animal health company specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished formulations. Its product portfolio covers a wide range of therapeutic areas including anthelmintics, anti-infectives, and nutraceuticals, alongside analytical testing services for the pharmaceutical and personal care sectors.
Business Model
The company generates revenue through the sale of animal health APIs and finished dosage forms, supported by a global manufacturing and distribution footprint. Additionally, it provides specialised analytical solutions, including method validation and stability testing, to external pharmaceutical and nutraceutical organisations.
Growth Outlook
Growth is driven by the expansion of its animal health product portfolio and the increasing demand for high-quality veterinary APIs and formulations globally. The company continues to leverage its analytical capabilities to support both internal development and external client requirements.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent global regulatory standards for pharmaceutical manufacturing and the potential for audits impacting production.
- Input Cost Volatility. Fluctuations in the prices of raw materials and key starting materials for APIs can significantly impact profit margins.
- Foreign Exchange Risk. As a global player with significant international operations, the company is exposed to currency fluctuations that may affect financial performance.
- Competitive Landscape. The animal health sector is highly competitive, requiring continuous investment in research and development to maintain market share.
Start your research today
Unlock AI insights, financials, peers and live data on Viyash Scientific Ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,644 Cr
TTM · consolidated
NET PROFIT
₹152 Cr
TTM · consolidated
EPS
₹3.25
TTM · consolidated
RETURN ON EQUITY
8.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
13.0%
TTM · consolidated
P/E
81.8x
Q4 FY26 · consolidated
EV/EBITDA
23.4x
Q4 FY26 · consolidated
EBITDA MARGIN
19.1%
TTM · consolidated
NET PROFIT MARGIN
7.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.1x
Q4 FY26 · consolidated
Peers · Pharma - CDMO/API
As of Q4 FY26